Noel Raynal

Formation

• Post-doctorat (2009-2013) MD Anderson Cancer Center, Department of Leukemia, University of Texas et Fels Institute for Cancer Research and Molecular Biology, Temple University
• Ph. D. en Biologie, INRS-Institut Armand-Frappier, Université du Québec (2003-2008)
• M.Sc. en Biologie, Université du Québec à Montréal (2001-2003)
• Licence de Biochimie, Université de Montpellier (2000)

Thèmes de recherche du laboratoire

• Étude des mécanismes d’action de nouveaux médicaments épigénétiques dans le traitement des cancers pédiatriques
• Criblage de nouvelles combinaisons de médicaments épigénétiques
• Culture cellulaire en 3D

Membres du laboratoire

• Mariya Kryvoshey, étudiante à la maîtrise
• Emmanuel Sy, étudiant à la maîtrise
• Walid Mardhy, étudiant à la maîtrise
• Anaïs Darracq, stagiaire postdoctorale
• Marielle Huot, assistante de recherche
• Nicolas Sgarioto, assistant de recherche

Publications choisies

• Somnath Pandey, Rahinatou Djibo, Anaïs Darracq, Gennaro Calendo, Hanghang Zhang, Ryan A. Henry, Andrew J. Andrews, Steven Baylin, Jozef Madzo, Rafael Najmanovich, Jean-Pierre J. Issa & Noël J.M. Raynal. Selective CDK9 inhibition by natural compound toyocamycin in cancer cells. Cancers 2022, 14, 3340.
• Repurposing proscillaridin A in combination with decitabine against embryonal rhabdomyosarcoma RD cells.
  Huot M, Caron M, Richer C, Djibo R, Najmanovich R, St-Onge P, Sinnett D, Raynal NJM.
  Cancer Chemother Pharmacol. 2021 Jul 31.
• Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
  Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson JY, Richard S, Raynal NJ.
  Clin Epigenetics. 2021 Mar 10;13(1):54.

• Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation.
  Da Costa EM, Armaos G, McInnes G, Beaudry A, Moquin-Beaudry G, Bertrand-Lehouillier V, Caron M, Richer C, St-Onge P, Johnson JR, Krogan N, Sai Y, Downey M, Rafei M, Boileau M, Eppert K, Flores-Díaz E, Haman A, Hoang T, Sinnett D, Beauséjour C, McGraw S, Raynal NJ.
  J Exp Clin Cancer Res. 2019 Jun 13;38(1):251.

• TACIMA-218: A Novel Pro-Oxidant Agent Exhibiting Selective Antitumoral Activity.
  Abusarah J, Cui Y, El-Hachem N, El-Kadiry AE, Hammond-Martel I, Wurtele H, Beaudry A, Raynal NJ, Robert F, Pelletier J, Jankovic M, Mercier F, Kamyabiazar S, Annabi B, Rafei M.
  Mol Cancer Ther. 2021 Jan;20(1):37-49.

• Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.
  Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J, Raynal NJ, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ.
  Cell. 2018 Nov 15;175(5):1244-1258.e26.

• DNA Methylation-Targeted Drugs.
  Da Costa EM, McInnes G, Beaudry A, Raynal NJ.
  Cancer J. 2017 Sep/Oct;23(5):270-276.

• Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
  Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ.
  Mol Cancer Ther. 2017 Feb;16(2):397-407.

• • Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.
    Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews AJ, Jelinek J, Cui Y, Baylin SB, Gill DL, Issa JP.
    Cancer Res. 2016 Mar 15;76(6):1494-505.